Eye tracking study for children with Angelman syndrome
Part of Brain & nervous system, Genetic & congenital clinical trials.
This trial uses eye tracking to understand how children with Angelman syndrome perceive social cues. Participation helps researchers learn more about social perception for future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Children aged 3 to 17 years
- Diagnosis of Angelman syndrome confirmed by genetic testing or EEG
- Parent or guardian must give permission and the child must not object
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with Angelman syndrome over time to learn more about the condition. It does not test any new treatments, but you need a parent or caregiver to come with you to all visits.
This trial is building a global registry for people diagnosed with Angelman syndrome. It helps researchers learn more about how symptoms change over time, which can support future studies and treatments.
This study tests an experimental medicine for Angelman syndrome (AS), a genetic condition affecting the nervous system. The medicine is given by lumbar puncture and aims to improve symptoms.
This study follows people with Angelman syndrome to understand how their symptoms and development change over time. It may help researchers better describe the condition and support future treatments.
This study follows people with Angelman syndrome over time to learn more about the condition. You can join if you have a confirmed genetic diagnosis and your caregiver agrees to take part.
This study uses an eye-tracking tool (it measures where and how your eyes move) to assess how people process social information. It aims to build a standard way to evaluate social processing in children and in comparison groups without these diagnoses.
Hear when a new Angelman Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.